Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs State Street Technology Select Sector SPDR ETF (XLK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs State Street Technology Select Sector SPDR ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $300.47 (market cap $39.89B), while State Street Technology Select Sector SPDR ETF trades at $183.82. The key difference: State Street Technology Select Sector SPDR ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | XLK | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Sector/Thematic |
52-Week High | $491.22 | $198.21 |
52-Week Low | $278.09 | $127.49 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
XLK, the Technology Select Sector SPDR ETF, trades at $185.79, up 0.24% today, with a bullish technical signal driven by moving averages. It has gained 33% year-to-date as of July 2026, outperforming the Nasdaq-100, supported by strong tech earnings and sector inflows. A dividend of $0.23 is scheduled for June 2026.
The outlook remains positive given robust tech fundamentals and institutional optimism, but risks include market concentration, Fed policy shifts, and potential valuation pressures. Wall Street sentiment is bullish, though some investors are reducing mega-cap tech exposure ahead of key guidance updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About State Street Technology Select Sector SPDR ETF
XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →
